Press releaseGlobe Newswire
60 Degrees Pharmaceuticals
SXTPW · NASDAQ
$0.026+$0.0007 (+2.77%)TodayMarket closed ·
Prev close $0.0253
Latest news
- Press releaseGlobe Newswire
60 Degrees Pharmaceuticals Announces Minimum Enrollment Achieved in Hospitalized Babesiosis Study; Interim Data Readout Planned by October 6, 2026
- Press releaseGlobe Newswire
60 Degrees Pharmaceuticals Announces Exclusive Option Agreement with Florida State University to Advance Castanospermine for Tick-Borne Diseases
- Press releaseGlobe Newswire
60 Degrees Pharmaceuticals Announces 2025 Annual Results
- Press releaseGlobe Newswire
60 Degrees Pharmaceuticals Exercises License Option with Florida State University for Large-Scale Purification of Castanospermine for Non-Rx Use
- Press releaseGlobe Newswire
60 Degrees Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference
- Press releaseGlobe Newswire
60 Degrees Pharmaceuticals Announces 2024 Annual Results
- Press releaseGlobe Newswire
60 Degrees Pharma Provides University of Kentucky with Right of Reference to ARAKODA® NDA in Support of SJ733 Phase IIb Study
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.